Edition:
United Kingdom

Protagonist Therapeutics Inc (PTGX.OQ)

PTGX.OQ on NASDAQ Stock Exchange Global Market

9.06USD
20 Aug 2018
Change (% chg)

-- (--)
Prev Close
$9.06
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
76,180
52-wk High
$23.68
52-wk Low
$5.92

Latest Key Developments (Source: Significant Developments)

Protagonist Therapeutics Reports Second Quarter 2018 Financial Results
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Protagonist Therapeutics Inc ::PROTAGONIST THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.PROTAGONIST THERAPEUTICS INC QUARTERLY NET LOSS PER SHARE $0.41.  Full Article

Protagonist Therapeutics Secures $22 Million Equity Financing
Monday, 6 Aug 2018 

Aug 6 (Reuters) - Protagonist Therapeutics Inc ::PROTAGONIST THERAPEUTICS SECURES $22 MILLION EQUITY FINANCING.PROTAGONIST THERAPEUTICS - SIGNED SECURITIES PURCHASE AGREEMENT FOR SALE OF 2.75 MILLION SHARES OF COMMON STOCK.  Full Article

Protagonist Therapeutics Discontinues Phase 2B Propel Trial Of PTG-100
Monday, 26 Mar 2018 

March 26 (Reuters) - Protagonist Therapeutics Inc ::PROTAGONIST THERAPEUTICS DISCONTINUES PHASE 2B PROPEL TRIAL OF PTG-100 FOR THE TREATMENT OF ULCERATIVE COLITIS FOLLOWING INTERIM ANALYSIS.PROTAGONIST THERAPEUTICS - USING PRE-SPECIFIED CRITERIA, DMC DEEMED TRIAL TO BE FUTILE BASED ON AN ANALYSIS OF PRIMARY ENDPOINT OF CLINICAL REMISSION.PROTAGONIST THERAPEUTICS INC - NO SAFETY CONCERNS WERE NOTED IN ANALYSIS.PROTAGONIST THERAPEUTICS INC - ‍DECISION FOLLOWED A PLANNED INTERIM ANALYSIS BY AN INDEPENDENT DATA MONITORING COMMITTEE​.PROTAGONIST THERAPEUTICS- TO POSTPONE DECISION ABOUT INITIATION OF PHASE 2/3 CLINICAL TRIAL OF PTG-100 IN CHRONIC POUCHITIS.PROTAGONIST THERAPEUTICS- TO POSTPONE DECISION ABOUT INITIATION OF PHASE 2/3 CLINICAL UNTIL AFTER FULL REVIEW OF INTERIM DATA FROM UC PROPEL STUDY.  Full Article

Protagonist Therapeutics initiates phase 1 trial of oral peptide PTG-200
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Protagonist Therapeutics Inc : :Protagonist Therapeutics initiates phase 1 trial of oral peptide IL-23 receptor antagonist, PTG-200.Protagonist Therapeutics - co is developing PTG-200 in collaboration with Janssen.  Full Article

Protagonist Therapeutics Q3 ‍net loss per share $0.29​
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Protagonist Therapeutics Inc :Protagonist Therapeutics reports third quarter 2017 financial results and provides corporate update.Protagonist Therapeutics Inc qtrly ‍net loss per share attributable to common stockholders was $0.29​.  Full Article

Protagonist Therapeutics prices offering of 3.53 mln common shares at $17 per share
Thursday, 12 Oct 2017 

Oct 11 (Reuters) - Protagonist Therapeutics Inc :Prices public offering of common stock.Says public offering of 3.53 million common shares priced at $17.00 per share.  Full Article

Protagonist Therapeutics announces proposed public offering of common stock
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Protagonist Therapeutics Inc :Protagonist Therapeutics announces proposed public offering of common stock.Protagonist Therapeutics -to use proceeds to fund clinical research, development of co's three therapeutic candidates, PTG-100, PTG-200, and PTG-300​.  Full Article